Viemed Healthcare Announces Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue reached a record $80.7 million, up 12.2% year over year
- ➤Q3 net income rose 32.0% year over year to $4.6 million
- ➤Adjusted EBITDA increased 5.8% year over year to $17.1 million
- ➤2026 revenue guidance floor raised to $316 million; EBITDA range narrowed to $64-$66 million
- ➤Net capital expenditure outlook lowered to 8.0%-9.0% of revenue
Expert Statements
Casey Hoyt, CEO of Viemed
“Viemed delivered another record quarter, with revenue reaching $80.7 million and continued growth across our respiratory, sleep, and women's health businesses. This marks our first full year-over-year quarterly comparison following the Lehan acquisition, and achieving double-digit revenue growth underscores the strength of our increasingly diversified platform and the opportunities ahead of us.”
Casey Hoyt, CEO of Viemed
“We are particularly pleased with the improvement in profitability this quarter. Our attributable net income increased 68% sequentially, while Adjusted EBITDA grew 24%, significantly outpacing revenue growth and demonstrating improved operating leverage. These results reflect the progress we anticipated following our investments earlier this year, and we see additional opportunities to improve efficiency as those initiatives mature. We remain focused on expanding our reach, delivering high-quality patient care, and building on this momentum as we finish the year.”
LAFAYETTE, LA / ACCESS Newswire / November 4, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three and nine months ended September 30, 2026, and updated guidance for the full year ending December 31, 2026.
Third Quarter 2026 Financial and Operational Highlights (all dollar amounts are USD): * Net revenue for the quarter ended September 30, 2026 totaled a Company record $80.7 million, an increase of $8.8 million, or 12.2%, compared with the prior-year quarter, and 3.3% sequentially. * Net income attributable to Viemed totaled $4.6 million, or $0.11 per diluted share, an increase of 32.0% compared to $3.5 million, or $0.09 per diluted share, in the prior-year quarter, and a 67.8% sequential increase from $2.8 million in the second quarter of 2026. Net income attributable to Viemed represented 5.7% of net revenue, compared to 3.5% in the preceding quarter. * Adjusted EBITDA totaled $17.1 million, an increase of 5.8% year over year and 24.4% sequentially. Adjusted EBITDA as a percentage of net revenue increased to 21.1%, compared to 17.6% in the second quarter of 2026, representing an improvement of approximately 350 basis points. * Ventilator rental revenue increased 7.4% year over year to $37.5 million, supported by higher average patient volumes. The Company's period-end ventilator patient count totaled 12,552 as of September 30, 2026. * PAP therapy patients increased 37.5% year over year and 16.0% sequentially to 43,861 during the third quarter. Sleep resupply patients increased 22.1% year over year and 10.5% sequentially to 40,918. * Net cash provided by operating activities totaled $11.5 million for the quarter and $53.9 million for the trailing twelve months ended September 30, 2026. Free cash flow totaled $4.0 million for the quarter and $26.1 million for the trailing twelve months ended September 30, 2026. * The Company ended the quarter with $9.7 million in cash, $12.0 million in working capital, and approximately $46 million available under its existing credit facilities. During the quarter, the Company repaid $2.1 million of term debt and repurchased 115,000 common shares for approximately $1.0 million (excluding taxes). Updated Full Year 2026 Guidance (all dollar amounts are USD):
Get started
Create a free account to read the full story.